BR112012003809A2 - anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo. - Google Patents

anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.

Info

Publication number
BR112012003809A2
BR112012003809A2 BR112012003809A BR112012003809A BR112012003809A2 BR 112012003809 A2 BR112012003809 A2 BR 112012003809A2 BR 112012003809 A BR112012003809 A BR 112012003809A BR 112012003809 A BR112012003809 A BR 112012003809A BR 112012003809 A2 BR112012003809 A2 BR 112012003809A2
Authority
BR
Brazil
Prior art keywords
individual
composition
monoclonal antibody
antigen binding
binding portion
Prior art date
Application number
BR112012003809A
Other languages
English (en)
Portuguese (pt)
Inventor
Schoeberl Birgit
Feldhaus Mechael
Nielsen Ulrrik
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012003809(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of BR112012003809A2 publication Critical patent/BR112012003809A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112012003809A 2009-08-21 2010-08-23 anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo. BR112012003809A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
PCT/US2010/046364 WO2011022727A2 (fr) 2009-08-21 2010-08-23 Anticorps contre l’ectodomaine de erbb3 et leurs utilisations

Publications (1)

Publication Number Publication Date
BR112012003809A2 true BR112012003809A2 (pt) 2019-09-24

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012003809A BR112012003809A2 (pt) 2009-08-21 2010-08-23 anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.

Country Status (21)

Country Link
EP (1) EP2467164A2 (fr)
JP (1) JP5752687B2 (fr)
KR (1) KR20120059568A (fr)
CN (1) CN103002912A (fr)
AU (1) AU2010284018C1 (fr)
BR (1) BR112012003809A2 (fr)
CA (1) CA2771744A1 (fr)
CR (1) CR20120108A (fr)
DO (1) DOP2012000044A (fr)
EA (1) EA201200195A1 (fr)
EC (1) ECSP12011740A (fr)
IL (1) IL218097A0 (fr)
IN (1) IN2012DN01518A (fr)
MA (1) MA33582B1 (fr)
MX (1) MX336091B (fr)
NI (1) NI201200027A (fr)
PE (1) PE20121585A1 (fr)
SG (1) SG178509A1 (fr)
TN (1) TN2012000057A1 (fr)
WO (1) WO2011022727A2 (fr)
ZA (1) ZA201201195B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579644A (en) 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
KR101806323B1 (ko) 2009-11-13 2017-12-07 다이이치 산쿄 유럽 게엠베하 Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법
PH12012501157A1 (en) 2009-12-22 2012-10-29 Roche Glycart Ag Anti-her3 antibodies and uses thereof
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
KR101764453B1 (ko) 2010-04-09 2017-08-02 아베오 파마슈티컬즈, 인크. 항-erbb3 항체
ME02637B (fr) 2010-08-20 2017-06-20 Novartis Ag Anticorps pour le récepteur 3 du facteur de croissance épidermique (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
WO2012059857A2 (fr) 2010-11-01 2012-05-10 Symphogen A/S Composition d'antcorps pan-her
MX336197B (es) * 2011-04-19 2016-01-11 Merrimack Pharmaceuticals Inc Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
WO2012176779A1 (fr) * 2011-06-20 2012-12-27 協和発酵キリン株式会社 Anticorps anti-erbb3
WO2013048883A2 (fr) 2011-09-30 2013-04-04 Regeneron Pharmaceuticals, Inc. Anticorps anti-erbb3 et leurs utilisations
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
EP2764364B1 (fr) 2011-10-06 2021-08-18 Aveo Pharmaceuticals, Inc. Prédiction de réaction de tumeur à des anticorps anti-erbb3
WO2013071058A1 (fr) * 2011-11-09 2013-05-16 The Uab Research Foundation Anticorps her3 et utilisations de ceux-ci
CN108341873B (zh) 2011-12-05 2022-03-25 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
US20150037336A1 (en) * 2012-02-22 2015-02-05 U3 Pharma Gmbh Combination of hb-egf binding protein and egfr inhibitor
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
WO2015100459A2 (fr) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
CA2941030C (fr) 2014-02-28 2025-05-13 Merus N.V. Anticorps qui se lient à l'egfr et à l'erbb3
CN105367657B (zh) * 2014-08-14 2019-09-13 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016038610A1 (fr) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions et procédés de traitement d'un cancer résistant à un inhibiteur de la tyrosine kinase (tki)
US10526416B2 (en) 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
JP7296728B2 (ja) 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
EP3625264B9 (fr) 2017-05-17 2023-10-25 Merus N.V. Combinaison d'un anticorps bispecifique erbb-2 / erbb-3 avec une therapie endocrine pour le cancer du sein
US11390686B2 (en) 2017-08-09 2022-07-19 University Of Saskatchewan HER3 binding agents and uses thereof
RS66708B9 (sr) 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
WO2019241893A2 (fr) * 2018-06-22 2019-12-26 Crd Pharmaceuticals Inc Anticorps anti-her3 et ses utilisations
CN116133694B (zh) * 2020-10-14 2026-03-06 苏州盛迪亚生物医药有限公司 抗her3抗体和抗her3抗体药物偶联物及其医药用途
EP4247430A4 (fr) * 2020-11-20 2024-12-11 Actinium Pharmaceuticals, Inc. Radioimmunothérapie de her3 pour le traitement de cancers solides
EP4355787A4 (fr) * 2021-06-15 2025-04-30 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Anticorps anti-her3, conjugué anticorps-médicament le contenant et son utilisation
WO2023198138A1 (fr) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Anticorps ou fragment de liaison à l'antigène de celui-ci et son utilisation médicale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ579644A (en) * 2007-02-16 2012-05-25 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof

Also Published As

Publication number Publication date
WO2011022727A3 (fr) 2013-06-27
WO2011022727A2 (fr) 2011-02-24
CA2771744A1 (fr) 2011-02-24
TN2012000057A1 (en) 2013-09-19
EP2467164A2 (fr) 2012-06-27
KR20120059568A (ko) 2012-06-08
CN103002912A (zh) 2013-03-27
ECSP12011740A (es) 2013-02-28
MX2012002172A (es) 2012-05-29
CR20120108A (es) 2012-06-05
ZA201201195B (en) 2015-07-29
DOP2012000044A (es) 2012-06-30
AU2010284018C1 (en) 2015-10-15
MX336091B (es) 2016-01-08
AU2010284018A1 (en) 2012-03-22
JP5752687B2 (ja) 2015-07-22
EA201200195A1 (ru) 2012-12-28
AU2010284018B2 (en) 2014-06-05
SG178509A1 (en) 2012-04-27
IL218097A0 (en) 2012-04-30
NI201200027A (es) 2013-01-29
JP2013506622A (ja) 2013-02-28
IN2012DN01518A (fr) 2015-06-05
MA33582B1 (fr) 2012-09-01
PE20121585A1 (es) 2012-11-29

Similar Documents

Publication Publication Date Title
BRPI0811907A2 (pt) Anticorpos monoclonais contra claudina-18 para tratamento de câncer.
BRPI0916945A2 (pt) métodos para tratar uma doença auto-imune ou distúrbio inflamatório em um indivíduo humano, para tratar esclerose múltipla em um indivíduo, e para identificar anticorpos, anticorpo humano, humanizado ou quimérico isolado ou um fragmento de ligação de antígeno do mesmo, e, proteína de ligação isolada.
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BR112014011028A2 (pt) molécula de ligação isolada ou fragmento de ligação de antígeno da mesma, anticorpo biespecífico, molécula de polinucleotídeo isolada, composição, método para a prevenção ou tratamento de uma infecção por pseudomonas em um indivíduo, e, kit
BRPI0821447A2 (pt) Anticorpo de alvejamento engenheirado, composição farmacêutica, hibridoma, ensaio com base em anticorpo, polipeptídeo isolado, e, método para ligação homogênea
BRPI0918178A2 (pt) anticorpos monoclonais para tratamento de câncer
IL219653A0 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BRPI0821168A2 (pt) anticorpo, hibridoma, e, métodos para tratar doenças em um paciente e para tratar um paciente de transplante
BRPI0822447A2 (pt) Anticorpo monoclonal e método do mesmo
ZA201002313B (en) Human antibodies that bind mesothelin,and uses thereof
BRPI1013177A2 (pt) construto de ligação de antígeno, polipeptídeo isolado, e, método para tratar doença cardíaca
BR112014000263A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica
LT3421498T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
IL206108A (en) Antibody @ Bi-value @ Bi-specific L @ method for its preparation, compounds containing it @ and cell @ surrogate
BRPI0923199A2 (pt) métodos e composições para detecção de anticorpos com fixação de complemento.
IL234081B (en) Cross - species - specific cd3 - epsilon binding antibody
NO20083891L (no) Anti-5T4 antistoffer og anvendelser derav
BR112014018481A2 (pt) anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso
BRPI0808814A2 (pt) Anticorpos monoclonais para o tratamento do câncer
BR112014002618A2 (pt) anticorpo ou um fragmento do mesmo, que tem reatividade imunológica com uma proteína caprin-1, composição farmaceutica e combinação farmacêutica para tratamento e/ou prevenção de câncer, dna e método para tratamento e/ou prevenção de cãncer
PL3181581T3 (pl) Przeciwciała o zmodyfikowanym powinowactwie do FcRn, które wspomagają klierens antygenu
BRPI0905761A2 (pt) Anticorpo humanizado ou fragmento de ligação ao mesmo, ácido nucléico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou o fragmento de ligação ao mesmo, composição, método para tratar uma doença ou distúrbio mediado por vwf em um indivíduo, uso de um anticorpo humanizado ou fragmento de ligação do mesmo, método para administração do anticorpo humanizado ou fragmento de ligação do mesmo, artigo de fabricação e kit
BRPI1008441A2 (pt) anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira.
EP3722313A4 (fr) Anticorps ou son fragment de liaison à l'antigène pour reconnaître spécifiquement une malignité de cellule b, récepteur d'antigène chimérique le comprenant, et son utilisation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.